Demographic characteristics of NIH cGVHD cohort
| Total number of patients . | n (%) or (range) . |
|---|---|
| All | 206 |
| Adult | 189 (92) |
| Pediatric | 17 (8) |
| Number with ScGVHD of skin | 109 (53) |
| Median BSA sclerosis (adults) | 37.40% |
| Median age, y | 46 (3-70) |
| Sex | |
| Male | 112 (54) |
| Female | 94 (46) |
| Disease | |
| ALL/AML/MDS | 89 (43) |
| CML | 30 (15) |
| CLL | 14 (7) |
| Lymphoma | 42 (20) |
| Multiple myeloma | 15 (7) |
| Aplastic anemia/PNH | 8 (4) |
| Other | 8 (4) |
| Conditioning regimen | |
| Myeloablative | 116 (56) |
| Reduced intensity | 88 (43) |
| Unknown | 2 (1) |
| Stem cell source | |
| BM | 40 (20) |
| Peripheral blood | 159 (77) |
| Cord | 7 (3) |
| Relationship | |
| Related | 136 (66) |
| Unrelated | 70 (34) |
| Sex mismatch | |
| M/M | 50 (25) |
| M/F | 48 (24) |
| F/F | 41 (20) |
| F/M | 45 (22) |
| Unknown | 20 (9) |
| HLA matched | |
| Yes | 167 (81) |
| No | 36 (17) |
| Unknown | 3 (2) |
| Days from transplantation | 1089 (49-1406) |
| cGVHD onset | |
| Progressive | 94 (46) |
| Quiescent | 43 (21) |
| De Novo | 68 (33) |
| Unknown | 1 (0) |
| Median cGVHD treatments | 4 (0-8) |
| GVHD involvement | |
| Skin | 151 (78)* |
| Joints and fascia | 115 (59) |
| Ocular | 157 (81) |
| Mouth | 132 (68) |
| Lung | 145 (75) |
| Liver | 101 (52) |
| GI | 86 (44) |
| Genital (females only) | 44 (47) |
| NIH Global Score | |
| Mild | 4 (2) |
| Moderate | 67 (35) |
| Severe | 123 (63) |
| Total number of patients . | n (%) or (range) . |
|---|---|
| All | 206 |
| Adult | 189 (92) |
| Pediatric | 17 (8) |
| Number with ScGVHD of skin | 109 (53) |
| Median BSA sclerosis (adults) | 37.40% |
| Median age, y | 46 (3-70) |
| Sex | |
| Male | 112 (54) |
| Female | 94 (46) |
| Disease | |
| ALL/AML/MDS | 89 (43) |
| CML | 30 (15) |
| CLL | 14 (7) |
| Lymphoma | 42 (20) |
| Multiple myeloma | 15 (7) |
| Aplastic anemia/PNH | 8 (4) |
| Other | 8 (4) |
| Conditioning regimen | |
| Myeloablative | 116 (56) |
| Reduced intensity | 88 (43) |
| Unknown | 2 (1) |
| Stem cell source | |
| BM | 40 (20) |
| Peripheral blood | 159 (77) |
| Cord | 7 (3) |
| Relationship | |
| Related | 136 (66) |
| Unrelated | 70 (34) |
| Sex mismatch | |
| M/M | 50 (25) |
| M/F | 48 (24) |
| F/F | 41 (20) |
| F/M | 45 (22) |
| Unknown | 20 (9) |
| HLA matched | |
| Yes | 167 (81) |
| No | 36 (17) |
| Unknown | 3 (2) |
| Days from transplantation | 1089 (49-1406) |
| cGVHD onset | |
| Progressive | 94 (46) |
| Quiescent | 43 (21) |
| De Novo | 68 (33) |
| Unknown | 1 (0) |
| Median cGVHD treatments | 4 (0-8) |
| GVHD involvement | |
| Skin | 151 (78)* |
| Joints and fascia | 115 (59) |
| Ocular | 157 (81) |
| Mouth | 132 (68) |
| Lung | 145 (75) |
| Liver | 101 (52) |
| GI | 86 (44) |
| Genital (females only) | 44 (47) |
| NIH Global Score | |
| Mild | 4 (2) |
| Moderate | 67 (35) |
| Severe | 123 (63) |
Values are n (%) unless otherwise specified.
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BSA, body surface area; cGVHD, chronic GVHD; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; F, female; M, male; MDS, myelodysplastic syndrome; NIH, National Institutes of Health; PNH, paroxysmal nocturnal hemoglobinuria; and ScGVHD, sclerotic-type chronic GVHD.
Includes both sclerotic and nonsclerotic dermatologic manifestations of cGVHD.